Abstract 465P
Background
Diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive pediatric central nervous system tumors, and currently, there are no curative treatment options available. With the increasing application of molecular diagnostics, more and more DIPG patients are recommended to undergo surgery; however, its correlation with dissemination needs to be better understood. Hence, we conducted this cohort to analyze the predictors of subsequent metastasis in pediatric DIPGs.
Methods
The final analysis included 142 pediatric (age ≤ 12) DIPG patients treated at Sanjiu Brain Hospital between January 2017 and September 2023. The data were retrospectively collected following the initial diagnosis. Patients were followed up for 6 months. The primary endpoint was the occurrence of subsequent metastasis. Univariable and multivariable logistic regression analyses were utilized to identify statistically significant predictors of subsequent dissemination. All statistical assessments were two-tailed, and only P < 0.05 was deemed to be statistically significant.
Results
Among 142 patients, 14 (9.9%) developed metastasis within the follow-up time. There were 77 (54.2%) males and 65 (45.8%) females. The median age was 7 years (ranging 1 - 12 years). The overall cohort demonstrated that surgery was the only predictor of dissemination both in univariable (OR 4.567, 95%CI 1.351 – 20.901, P = 0.024) and multivariable (OR 5.501, 95%CI 1.560 – 26.105, P = 0.014) analyses. However, subgroup analysis involving patients who received surgical intervention showed that biopsy was not superior nor inferior to resection in terms of relative risk for subsequent dissemination (16.7% vs. 15.8%).
Conclusions
Surgical intervention increases the relative risk of dissemination occurrence to four times more than those who did not receive surgery. Surgical intervention is crucial given the potential of molecular analysis leading to improved therapeutic options. Nonetheless, patients should be informed about the risks associated with surgery, including subsequent metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
489P - Interfering with the tumor microenvironment of glioblastoma: An in vitro study
Presenter: Serena Mastantuono
Session: Poster session 16
490P - Inhibiting glioma cells' migration: Exploring Rho-GTPases as a potential therapeutic target
Presenter: Irene Giulia Rolle
Session: Poster session 16
Resources:
Abstract
491P - SRSF7 promotes glioblastoma progression via CDK1-mediated G2/M phase arrest of GBM cells
Presenter: Ya qin Hu
Session: Poster session 16
Resources:
Abstract
492P - Linking cellular drug responses to corresponding metabolomic tissue signatures in gliomas
Presenter: Stefanie Stanzer
Session: Poster session 16
493P - The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
Presenter: Kreina Vega Cano
Session: Poster session 16
494P - Effect of a new method for operating electric field patches on scalp reactions in glioblastoma patients receiving tumor treating fields
Presenter: Jinghui Liu
Session: Poster session 16
Resources:
Abstract
495P - Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: A single-center retrospective analysis of 118 cases
Presenter: Feng Chen
Session: Poster session 16
496P - Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients
Presenter: Ariane Steindl
Session: Poster session 16
497P - Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
Presenter: Junmin Song
Session: Poster session 16